Safety, Tolerability and Efficacy of BFH772 in Rosacea Patients
Status:
Completed
Trial end date:
2012-02-01
Target enrollment:
Participant gender:
Summary
This study will evaluate the safety, tolerability and efficacy of BFH772 after 12 weeks of
treatment as compared to an active control and vehicle in patients with
erythemato-telangiectatic rosacea.